Key binding characteristics of dusquetide to important intracellular protein identified

Paper published in the journal structure princeton, n.j. , june 1, 2022 /prnewswire/ -- soligenix, inc. (nasdaq: sngx) (soligenix or the company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today a publication describing the binding of its innate defense regulator (idr), dusquetide, to the p62 protein.
SNGX Ratings Summary
SNGX Quant Ranking